The Rising Prevalence Of Type 2 Diabetes Mellitus Is Fueling The Growth Of The Market Due To Increasing Cases Of Insulin Resistance And Pre-Diabetes Is Supporting Development Across The Incretin-Based Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Incretin-Based Drugs Market Compare Between 2026 And 2030?

The incretin-based drugs market size has experienced robust growth over recent years. This market is anticipated to expand from $27.83 billion in 2025 to $29.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historical market expansion can be linked to factors such as the widespread occurrence of type 2 diabetes, increasing rates of insulin resistance, the rise of lifestyle-related metabolic disorders, the adoption of endocrinology medications, and the implementation of hospital-based diabetes programs.

The incretin-based drugs market is anticipated to expand significantly over the coming years, with its size projected to reach $39.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected expansion during the forecast period stems from factors such as the global rise in obesity, the increasing need for weight management medications, breakthroughs in long-acting incretin therapies, the move towards individualized diabetes treatment, and a greater emphasis on proactive metabolic health. Key developments expected during this period involve the swift embrace of GLP-1 receptor agonists, broader applications for obesity management, a rise in the utilization of oral incretin treatments, the emergence of more combination therapy strategies, and enhanced patient compliance through once-weekly dosing regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Drivers Are Advancing The Incretin-Based Drugs Market Growth?

The expanding occurrence of type 2 diabetes mellitus is projected to stimulate the growth of the incretin-based drugs market in the coming years. This chronic metabolic condition is defined by insulin resistance and impaired insulin secretion, resulting in elevated blood glucose levels. The increase in type 2 diabetes is attributed to factors like poor diet and insufficient physical activity, which contribute to insulin resistance and hinder the body’s ability to regulate blood sugar. Incretin-based drugs work by enhancing insulin release after meals and lowering glucagon production, thereby assisting in blood sugar reduction. They further contribute to glucose control and weight management by delaying gastric emptying and suppressing appetite. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, about 549,000 more people in England were at risk of developing type 2 diabetes, increasing the total number with pre-diabetes to over 3.6 million, marking a nearly 20% rise from 2022. Thus, the escalating prevalence of type 2 diabetes mellitus is a key factor propelling the expansion of the incretin-based drugs market.

Which Segment Divisions Form The Structure Of The Incretin-Based Drugs Market?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Trends Are Driving Changes In The Incretin-Based Drugs Market?

Leading companies in the incretin-based drugs market are prioritizing the development of generic drug versions to offer more effective and convenient treatment options for type 2 diabetes. A generic drug is a medication that shares the same active ingredients, strength, dosage form, and method of administration as a brand-name drug, but is commercialized under its chemical name without brand identification. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical firm, launched the initial generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product gained approval from the Food and Drug Administration (FDA). It is indicated as an addition to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst ongoing shortages of GLP-1 medications.

Which Key Players Are Active In The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Access The Complete Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Accounts For The Highest Share Of The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Incretin-Based Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795